Navigation Links
Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income

LARGO, Fla., Nov. 21 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF; TSX Venture Exchange: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the first quarter ended September 30, 2008 (FY2009).

Net sales, excluding royalty income, increased 5.3% to $1,761,526 in FY2009 first quarter, compared with $1,673,361 in the previous year first quarter (FY2008). The increase was primarily a result of continued growth of the Company's C-Vue brand of specialty contact lenses, sold exclusively to licensed eye care professionals.

FY2009 first quarter net income increased 23.6% to a record first quarter of $466,367, or $.10 per diluted share, compared with $377,296 or $0.08 per diluted share in the previous year quarter.

Royalty income for the FY2009 first quarter increased 16.4% to a record first quarter of $713,397 compared with $612,799 in the prior-year quarter. Sales of licensed products by our licensee Bausch & Lomb continue to increase, resulting in continued double-digit royalty income growth.

FY2009 first quarter income before taxes increased 24.6% to a record first quarter $768,259 compared with $616,501 in the prior-year quarter. After recording net income tax expense of $301,892, Unilens reported net income of $466,367 for the quarter, or $0.10 per diluted share. In the FY2008 first quarter, the Company reported net income of $377,296, or $0.08 per diluted share, which included income tax expense of $239,205.

"We are pleased to report record first quarter sales, royalties and income for our FY2009 first quarter," stated Michael J. Pecora, Chief Executive Officer of Unilens Vision Inc. "Strong double-digit growth for our C-Vue brand of lenses sold exclusively to independent practitioners, combined with a 16% growth in royalty revenue derived from Bausch & Lomb's sales of multifocal lenses that use our key technologies, was responsible for this outstanding performance."

"I am also pleased to report that the Unilens' Board of Directors declared its regular quarterly dividend of US $0.09 per common share, payable next Friday November 28, 2008. "This decision was based on the Company's strong balance sheet, and projected operating cash flows and is consistent with the Board's commitment that shareholders should share directly in the earnings achieved by management while continuing to execute our growth strategy," concluded Mr. Pecora.

About Unilens Vision Inc. - "The Independent Eye Care Professionals Contact Lens Company"

Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue(R) brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVICF" as well as the Canadian TSX Venture Exchange under the symbol "UVI".

(Note: All financial information in this release is stated in U.S. Dollars.)

The information contained in this news release, other than historical information, consists of forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward- looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

    For more information, please contact:
    Leonard F. Barker, CFO, Unilens Vision Inc. at (727) 544-2531

                              UNILENS VISION INC.
                         FIRST QUARTER - FISCAL 2009

    (All figures in U.S. Dollars)
                                                  Three Months   Three Months
                                                     Ended          Ended
                                                 Sept. 30, 2008 Sept. 30, 2007

       Sales                                       $1,761,526     $1,673,361
       Cost of sales                                  935,132        904,397
                                                      826,394        768,964
       Expenses                                       771,961        754,952
       Income from operations                          54,433         14,012
       Other items:
       Royalty income                                 713,397        612,799
       Other income (expense)                           2,585        (27,141)
       Remeasurement (loss) income                     (4,427)         2,541
       Interest income                                  2,271         14,290
                                                      713,826        602,489
       Income before income tax                       768,259        616,501
       Income tax expense                             301,892        239,205
       Net income for the period                     $466,367       $377,296
       Net income per common share:
         Basic                                          $0.10          $0.08
         Diluted                                        $0.10          $0.08
    Provided (used) by:
       Operating activities                          $706,683       $689,258
       Investing activities                           (32,600)       (28,123)
       Financing activities                        (1,774,779)    (1,744,008)
       Decrease in cash                           $(1,100,696)   $(1,082,873)

                                                  Sept. 30, 2008 June 30, 2008
       Cash                                          $498,353     $1,603,476
       Total assets                                 5,432,149      6,784,128
       Current liabilities                            913,867        957,434
       Total liabilities                              913,867        957,434
       Stockholders' equity                        $4,518,282     $5,826,694

SOURCE Unilens Vision Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Unilens Launches New C-VUE(R) Advanced(TM) Custom Toric Lens
2. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
3. Unilens Vision Announces New Policies Aimed at Increasing Eye Care Professionals Profitability
4. Unilens Vision Reports Increased Royalty Income
5. Unilens Launches Aspheric C-VUE(R) Daily Disposable Lens
6. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
7. Unilens Vision Reports 70% Increase in Second Quarter Earnings on Higher Sales and Record Royalty Income
8. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
9. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
10. Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens
11. OmniVision Unveils 1.8 mm, Low Power Medical Sensor With Best-in-Class Low Light Performance
Post Your Comments:
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
(Date:6/23/2016)... YORK , June 23, 2016 ... waters, but it continues to present great opportunities to ... companies for today: Intrexon Corp. (NYSE: XON ... Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), and ... more about these stocks and receive your complimentary trade ...
Breaking Medicine Technology: